■术中和术后出血被认为是除皱术中最常见的风险之一。最近,抗纤维蛋白溶解剂在面部整形和重建手术中的使用已经被评估,但是它们在除皱术中的使用仍然是一个正在讨论的话题。氨甲环酸(TXA)是一种抗纤维蛋白溶解剂,通过阻断纤溶酶原向纤溶酶的转化来防止纤维蛋白凝块的酶降解,改善血小板功能,并具有直接的抗炎作用。这篇综述涵盖了相关文献,以阐明TXA在除皱术中的使用是否能赋予术中和术后益处。
■在在线数据库中进行了系统的文献检索:PubMed,谷歌学者,科克伦,Scopus,和WebofScience在6月之前发表的关于TXA改头换面主题的所有文章,2023年使用以下术语:“TXA,\"\"氨甲环酸,\"\"整形手术,\"\"美容手术,\"\"整容,\"\"除皱术\"。对它们进行单独或组合搜索。所有相关的原创研究文章,本综述纳入了所有研究设计,并进行了叙述性讨论。不包括在人类中进行的研究以及在其他专业中使用TXA的研究。包括英语语言。
■本文综述了8篇文章。通过这些文章,作者详细提供了TXA在整容患者中可能的有益效果,以评估几种临床结果:术中失血,术后引流输出,术后水肿,瘀斑,手术时间,和手术领域质量。
■尽管在整容患者中仍然缺乏有关TXA的信息,我们不能否认TXA对这个话题的有益影响。因此,进一步调查,包括前瞻性调查,应进行病例对照的多机构研究,比较分娩途径,直到达到,最后,以证据为基础的指南提供了关于TXA在整容中的给药和剂量的明确方案。
UNASSIGNED: Intraoperative and postoperative bleeding is considered one of the most common risks in rhytidectomy. Recently, the use of antifibrinolytic agents in facial plastic and reconstructive surgeries has been evaluated, but their use in rhytidectomy remains a topic of ongoing discussion. Tranexamic acid (TXA) is an antifibrinolytic agent that prevents enzymatic degradation of the fibrin clot by blocking the conversion of plasminogen to plasmin, improves platelet function, and has a direct anti-inflammatory effect. This review covers pertinent literature to elucidate whether the use of TXA in rhytidectomy confers intraoperative and postoperative benefits.
UNASSIGNED: A systematic literature search was conducted in online databases: PubMed, Google Scholar, Cochrane, Scopus, and Web of Science for all articles on the topic of TXA in
facelift published up to and including June, 2023 using the following terms: \"TXA,\" \"tranexamic acid,\" \"plastic surgery,\" \"aesthetic surgery,\" \"
facelift,\" \"rhytidectomy\". They were either searched individually or in combination. All relevant original research articles, of any study design were included and narratively discussed in this review. Studies not carried out in humans and studies centred on the use of TXA in other specialties were excluded. English Language was included.
UNASSIGNED: Eight articles were reviewed in this paper. Through these articles, the authors provided in detail the possible beneficial effects of TXA in
facelift patients in evaluating several clinical outcomes: intraoperative blood loss, postoperative drain output, postoperative oedema, ecchymosis, operative time, and surgical field quality.
UNASSIGNED: Although there is still a lack of information on TXA in
facelift patients, we are not able to deny the beneficial effects of TXA on this topic. Therefore, further investigations including prospective, case-controlled multi-institutional studies comparing routes of delivery should be performed until reaching, at the end, an evidence-based guideline providing a clear protocol in terms of the administration and dosage of TXA in
facelift.